Bank of America
CGTX icon

Bank of America’s Cognition Therapeutics CGTX Stock Holding History

Bank of America’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,735
Closed -$7.74K – 5920
2025
Q4 		$7.74K Buy
5,735
+140
+3% +$227 ﹤0.01% 6206
2025
Q3 		$7.55K Buy
5,595
+5,100
+1,030% +$6.96K ﹤0.01% 7241
2025
Q2 		$153 Buy
495
+190
+62% +$64 ﹤0.01% 7891
2025
Q1 		$128 Sell
305
-4,985
-94% -$2.93K ﹤0.01% 7781
2024
Q4 		$3.71K Buy
5,290
+11
+0.2% +$5 ﹤0.01% 7130
2024
Q3 		$2.47K Buy
5,279
+61
+1% +$63 ﹤0.01% 7099
2024
Q2 		$8.66K Buy
5,218
+218
+4% +$435 ﹤0.01% 6913
2024
Q1 		$9.1K Sell
5,000
-14
-0.3% -$29 ﹤0.01% 6902
2023
Q4 		$9.28K Buy
5,014
+14
+0.3% +$19 ﹤0.01% 6917
2023
Q3 		$7.2K Buy
+5,000
New +$7.83K ﹤0.01% 6928
2023
Q1 		– Sell
-46
Closed -$96 – 7847
2022
Q4 		$96 Buy
+46
New +$93 ﹤0.01% 7676

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Bank of America's CGTX Position: Q1 2026 in Review

Bank of America sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 5,735 shares — an estimated $7.74K sold.

Bank of America first reported a position in CGTX in Q4 2022 and held it in 11 quarters. The position peaked at $9.28K in Q4 2023. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Bank of America reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 5,735 Cognition Therapeutics shares in Q1 2026, an estimated $7.74K.
  • Bank of America first reported a position in Cognition Therapeutics in Q4 2022 and held it in 11 quarters.
  • Bank of America's Cognition Therapeutics position peaked at $9.28K in Q4 2023.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.